Nav: Home

'Inactive' ingredients may not be, study finds

March 13, 2019

CAMBRIDGE, MA -- Most pills and capsules, whether over-the-counter or prescription, include components other than the actual drug. These compounds, known as "inactive ingredients," help to stabilize the drug or aid in its absorption, and they can make up more than half of a pill's mass.

While these components are usually considered benign, a new study from MIT and Brigham and Women's Hospital has found that nearly all pills and capsules contain some ingredients that can cause allergic reactions or irritations in certain patients. In most cases, doctors have no idea which of these ingredients will be included in the pills they prescribe to their patients, because there are so many different formulations available for any given medication.

"For most patients, it doesn't matter if there's a little bit of lactose, a little bit of fructose, or some starch in there. However, there is a subpopulation of patients, currently of unknown size, that will be extremely sensitive to those and develop symptoms triggered by the inactive ingredients," says Daniel Reker, a Swiss National Science Foundation postdoc at MIT's Koch Institute for Integrative Cancer Research and one of the lead authors of the study.

The researchers hope that their study, published in the March 13 edition of Science Translational Medicine, will raise awareness of this issue among patients and health care providers and help to stimulate reforms that could protect patients from drugs that they don't tolerate well.

"Right now there is an imbalance in the amount of information and understanding out there with respect to the inactive components of medication," says Giovanni Traverso, an assistant professor in MIT's Department of Mechanical Engineering, a gastroenterologist at Brigham and Women's Hospital, and the senior author of the study.

Steven Blum, a clinical fellow at Dana-Farber Cancer Institute, is also a lead author of the paper. Other authors include Christoph Steiger, an MIT postdoc; and Kevin Anger, Jamie Sommer, and John Fanikos of the Investigational Drug Services at Brigham and Women's Hospital.

Unknown effects

Traverso began looking into this issue about five years ago following an experience involving a patient he was helping to look after. The patient, who had celiac disease, reacted poorly to omeprazole, a common acid suppressant used to treat stomach ulcers.

The specific formulation of omeprazole the patient had obtained contained ingredients derived from wheat products (potentially containing gluten). This information was only available from the manufacturer at the time. A week after obtaining the medication the patient had reported feeling sick from taking the medication.

"That really brought it home to me as far as how little we know about tablets and the potential adverse effects they might have," Traverso says. "I think there's a tremendous underappreciation of the potential impact that inactive ingredients may have."

Currently, when doctors write a prescription, they specify the type and dosage of the active pharmaceutical, but nothing about the inactive ingredients. Many medications come in dozens of different formulations, and the one that patients get depends on their insurance, their pharmacy, and the manufacturer that supplies the pharmacy. The information that comes with the medication usually lists inactive ingredients, but not the amounts of each one, and they may be difficult to decipher. For example, ingredients that contain gluten may not be listed as "gluten."

The researchers scoured medical journals and found several studies describing patients who had allergic reactions to inactive ingredients such as lactose and chemical dyes. These studies generally did not include patients with intolerances to a particular ingredient, which are milder and produce symptoms such as bloating or stomach ache. However, the researchers believe these milder reactions may affect many more patients. Potential problems could be especially prevalent among people over the age of 65, 30 percent of whom take at least five pills every day, potentially allowing critical ingredients to accumulate.

Next, the researchers set out to find as much as they could about the inactive ingredients found in prescription and nonprescription medications. Getting much of their information from a database called Pillbox, run by the National Library of Medicine, the researchers were able to determine the composition of nearly all prescription and over-the-counter medications available in the United States.

They found that for most medications, more than half of the pill is made up of inactive ingredients, and for some it is as high as 99 percent. They also found that about 93 percent of medications contain allergens such as peanut oil, lactose, or dyes, and nearly all contain compounds that some patients cannot tolerate, such as gluten and certain kinds of sugars. About 55 percent of medications contain sugars known as FODMAP sugars, which can trigger digestive problems in some people with irritable bowel syndrome.

When medications contain peanut oil, manufacturers print warnings on the labels, but for most other allergens or irritants, no warnings are given, and it is not easy to find out if a compound such as lactose or gluten is in the medicine, the researchers say. Even if patients are aware of their allergies and sensitivities and correctly decipher medication packages, many different treatments might not be available to them because not a single pill that avoids all these ingredients might exist, the researchers add.

Raising awareness

The researchers hope that their findings will help boost awareness of the potential risks that inactive ingredients pose for some patients. If new regulations could be implemented, requiring pharmaceutical companies to provide more information about the inactive ingredients in their formulations, it could be easier for doctors to specify whether a certain ingredient should not be included. The researchers also hope that pharmaceutical companies will develop more alternative formulations for patients with allergies or sensitivities to certain ingredients.

"I think all of these really need to come together," Traverso says. "Education, increased awareness, and legislation are all important."

The researchers are now working on a follow-up study in which they are polling health care providers to determine how widespread this problem may be. They also hope to perform clinical trials to study how much lactose or other common inactive ingredients manifest in symptoms in people who have intolerances to those ingredients.

"There need to be more clinical trials and more data out there so that we can really dive deep into how many patients are affected and how we can help them," Reker says.
-end-
The research was funded by the Swiss National Science Foundation, the Brigham and Women's Department of Medicine Residency Program and Division of Gastroenterology, the Alexander von Humboldt Foundation Feodor Lynen Fellowship, the National Institutes of Health, and the MIT-IBM Watson AI Lab.

Massachusetts Institute of Technology

Related Clinical Trials Articles:

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
Not enough women included in some heart disease clinical trials
Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology.
BU: Obese patients underrepresented in cancer clinical trials
A new review by Boston University School of Public Health researchers found that less than one-fifth of participants in cancer-related clinical trials are obese.
Are women really under-represented in clinical trials?
Several studies have reported a lack of gender diversity in clinical trials, with trials including mostly adult males; however, a recent review of publicly available registration data of clinical trials at the US Food and Drug Administration for the most frequently prescribed drug classes found no evidence of any systemic significant under-representation of women.
More Clinical Trials News and Clinical Trials Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#542 Climate Doomsday
Have you heard? Climate change. We did it. And it's bad. It's going to be worse. We are already suffering the effects of it in many ways. How should we TALK about the dangers we are facing, though? Should we get people good and scared? Or give them hope? Or both? Host Bethany Brookshire talks with David Wallace-Wells and Sheril Kirschenbaum to find out. This episode is hosted by Bethany Brookshire, science writer from Science News. Related links: Why Climate Disasters Might Not Boost Public Engagement on Climate Change on The New York Times by Andrew Revkin The other kind...
Now Playing: Radiolab

An Announcement from Radiolab